Repository logo
  • Log In
    New user? Click here to register.Have you forgotten your password?
University College Dublin
  • Colleges & Schools
  • Statistics
  • All of DSpace
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Science
  3. School of Biomolecular & Biomedical Science
  4. Biomolecular and Biomedical Science Research Collection
  5. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
 
  • Details
Options

Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor

File(s)
FileDescriptionSizeFormat
Download Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. .pdf5.2 MB
Author(s)
Sundaramurthi, Husvinee 
García-Mulero, Sandra 
Tonelotto, Valentina 
Slater, Kayleigh 
Marcone, Simone 
Piulats, J. M. 
Watson, R. William 
Tobin, Desmond John 
Jensen, Lasse D. 
Kennedy, Breandán 
Uri
http://hdl.handle.net/10197/13201
Date Issued
03 February 2022
Date Available
14T15:46:35Z October 2022
Abstract
Metastatic uveal melanoma (MUM) is characterized by poor patient survival. Unfortunately, current treatment options demonstrate limited benefits. In this study, we evaluate the efficacy of ACY-1215, a histone deacetylase inhibitor (HDACi), to attenuate growth of primary ocular UM cell lines and, in particular, a liver MUM cell line in vitro and in vivo, and elucidate the underlying molecular mechanisms. A significant (p = 0.0001) dose-dependent reduction in surviving clones of the primary ocular UM cells, Mel270, was observed upon treatment with increasing doses of ACY-1215. Treatment of OMM2.5 MUM cells with ACY-1215 resulted in a significant (p = 0.0001), dose-dependent reduction in cell survival and proliferation in vitro, and in vivo attenuation of primary OMM2.5 xenografts in zebrafish larvae. Furthermore, flow cytometry revealed that ACY-1215 significantly arrested the OMM2.5 cell cycle in S phase (p = 0.0001) following 24 h of treatment, and significant apoptosis was triggered in a time-and dose-dependent manner (p < 0.0001). Additionally, ACY-1215 treatment resulted in a significant reduction in OMM2.5 p-ERK expression levels. Through proteome profiling, the attenuation of the microphthalmia-associated transcription factor (MITF) signaling pathway was linked to the observed anti-cancer effects of ACY-1215. In agreement, pharmacological inhibition of MITF signaling with ML329 significantly reduced OMM2.5 cell survival and viability in vitro (p = 0.0001) and reduced OMM2.5 cells in vivo (p = 0.0006). Our findings provide evidence that ACY-1215 and ML329 are efficacious against growth and survival of OMM2.5 MUM cells.
Sponsorship
European Commission Horizon 2020
Other Sponsorship
Research Council—Enterprise Partnership Scheme 2020
Breakthrough Cancer Research
TopMed10—Marie Skłodowska-Curie Actions COFUND Programme
Type of Material
Journal Article
Publisher
MDPI
Journal
Cancers
Volume
14
Issue
3
Start Page
1
End Page
31
Copyright (Published Version)
2022 The Authors
Keywords
  • Metastatic uveal mela...

  • HDAC inhibitor

  • ACY-1215

  • MITF

  • p-ERK

  • ML329

  • Zebrafish xenografts

DOI
10.3390/cancers14030782
Language
English
Status of Item
Peer reviewed
ISSN
2072-6694
This item is made available under a Creative Commons License
https://creativecommons.org/licenses/by/3.0/ie/
Owning collection
Biomolecular and Biomedical Science Research Collection
Scopus© citations
6
Acquisition Date
Mar 27, 2023
View Details
Views
221
Last Month
5
Acquisition Date
Mar 27, 2023
View Details
Downloads
35
Last Month
4
Acquisition Date
Mar 27, 2023
View Details
google-scholar
University College Dublin Research Repository UCD
The Library, University College Dublin, Belfield, Dublin 4
Phone: +353 (0)1 716 7583
Fax: +353 (0)1 283 7667
Email: mailto:research.repository@ucd.ie
Guide: http://libguides.ucd.ie/rru

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement